Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age

HPV and Gynecologic Cancer

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Lancet.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A

doi: 10.1016/

HPV and Gynecologic Cancer

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age

Obstet Gynecol.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

doi: 10.1097/AOG.

HPV and Gynecologic Cancer

Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014

Obstet Gynecol.

Berenson AB, Hirth JM, Chang M

doi: 10.1097/

HPV and Gynecologic Cancer

Effectiveness Of Human Papillomavirus (HPV) Vaccination Against Penile Hpv Infection In Men Who Have Sex With Men And Transgender Women

J Infect Dis

Winer RL, Lin J, Querec TD, Unger ER, Stern JE, Rudd JM, Golden MR, Swanson F, Markowitz LE, Meites E

doi: 10.1093/infdis/jiab390

HPV and Gynecologic Cancer

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

BMJ Open.

Ramanakumar AV, Naud P, Roteli-Martins CM, de Carvalho NS, de Borba PC, Teixeira JC, Blatter M, Moscicki AB, Harper DM, Romanowski B, Tyring SK, Ramjattan B, Schuind A, Dubin G, Franco EL; HPV-007 Study Group

doi: 10.1136/

HPV and Gynecologic Cancer

Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine

J Low Genit Tract Dis.

Igidbashian S, Boveri S, Bottari F, Vidal Urbinati A, Preti E, Casadio C, Landoni F, Sideri M, Sandri MT.

doi: 10.1097/

HPV and Gynecologic CancerPregnancy and Childbirth

Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.

N Engl J Med.

Scheller NM, Pasternak B, Mølgaard-Nielsen D, Svanström H, Hviid A

doi: 10.1056/NEJMoa1612296.

HPV and Gynecologic Cancer

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Lancet Glob Health.

Abbas KM, van Zandvoort K, Brisson M, Jit M

doi: 10.1016/S2214-109X(20)30022-X.

HPV and Gynecologic Cancer

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Lancet.

Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group.

doi: 10.1016/S0140-6736(19)

Related content

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age

Change in Human Papillomavirus Prevalence Among U.S. Women Aged 18-59 Years, 2009-2014

Effectiveness Of Human Papillomavirus (HPV) Vaccination Against Penile Hpv Infection In Men Who Have Sex With Men And Transgender Women

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial

Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine

Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study

Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis